PMCTPharmaCountry
    ホーム

規制動向

FDA、EMA、TGA および世界の規制動向

#transdermal patch ×

UPDATED
規制動向
2026年9月10日•1分で読めます
FDA Approves TRANSDERM SCOP (NDA017874) Transdermal Scopolamine Patch
The FDA has approved the prescription transdermal patch TRANSDERM SCOP, containing 1 mg scopolamine per 72 hr, under NDA 017874. Baxter Healthcare is the manufacturer.
UPDATED
規制動向
2026年9月3日•1分で読めます
FDA Approves ANDA210272 for Buprenorphine Transdermal Patch
The FDA has approved application ANDA210272 for a buprenorphine transdermal patch, covering five dosage strengths and requiring a REMS program.